Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1111 KANE CONCOURSE, SUITE 301 BAY HARBOR ISLANDS FL 33154 |
Tel: | 1-781-6524500 |
Website: | https://www.fortressbiotech.com |
IR: | See website |
Key People | ||
Lindsay A. Rosenwald Executive Chairman of the Board, President, Chief Executive Officer | Eric K. Rowinsky Co-Vice Chairman of the Board | David Jin Chief Financial Officer, Corporate Secretary |
Michael S. Weiss Executive Vice Chairman - Strategic Development, Director | George C. Avgerinos Senior Vice President - Biologics Operations |
Business Overview |
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis in adults and children nine years and older. Accutane (isotretinoin) is an oral capsule for the treatment of severe recalcitrant nodular acne. Amzeeq (minocycline 4%) topical foam is a topical minocycline treatment for the inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and children nine years and older. Zilxi (minocycline 1.5%) is a topical foam and a topical minocycline treatment for inflammatory lesions of rosacea in adults. Ximino (minocycline hydrochloride) is an oral minocycline drug for the treatment of moderate to severe acne. |
Financial Overview |
For the nine months ended 30 September 2023, Fortress Biotech Inc revenues increased 9% to $64.6M. Net loss applicable to common stockholders decreased 13% to $57.4M. Revenues reflect Dermatology Product segment increase of 11% to $63.9M. Lower net loss reflects General and administarative decrease of 15% to $60.5M (expense), Research and developement decrease of 11% to $85.3M (expense). |
Employees: | 187 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $16.36M as of Sep 30, 2023 |
Annual revenue (TTM): | $80.97M as of Sep 30, 2023 |
EBITDA (TTM): | -$167.18M as of Sep 30, 2023 |
Net annual income (TTM): | -$84.33M as of Sep 30, 2023 |
Free cash flow (TTM): | -$150.03M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 18,376,750 as of Jan 3, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |